摘要
采用熔融乳化法制备非诺贝特纳米混悬剂,以粒径和ζ电位为指标,筛选优化处方。体外溶出试验显示,所制纳米混悬剂溶出速率显著高于原药和微粉化原药。大鼠体内药动学试验表明,纳米混悬剂组的AUC和c_(max)显著高于原药组和微粉化原药组。
The fenofibrate nanosuspension was prepared by melt-emulsification method and its formulation was optimized with diameter and ζ potential as indexes. The in vitro test showed that dissolution velocity of the prepared nanosuspension was faster than that of bulk and micronized fenofibrate. The pharmacokinetics in rats showed that the A UC and Cmax of the nanosuspension group were significantly higher than those of bulk group and micronized fenofibrate group.
出处
《中国医药工业杂志》
CAS
CSCD
北大核心
2009年第5期349-354,共6页
Chinese Journal of Pharmaceuticals
关键词
非诺贝特
纳米混悬剂
熔融-乳化法
高压均质
fenofibrate
nanosuspension
melt-emulsification
high pressure homogenization
